A financing and leadership expansion will accelerate the commercialization of Noctrix’s Nidra tonic motor activation therapy for restless legs syndrome. The funding and new appointments aim to accelerate the US launch and adoption of Nidra TOMAC therapy for restless legs syndrome. Noctrix Health Inc, the developer of the Nidra Tonic Motor Activation (TOMAC) therapy for restless legs syndrome (RLS), has secured a significant expansion of private financing to accelerate its US commercial launch. This will allow us to bring Nidra therapy to more patients with RLS expeditiously,” says Shri Raghunathan, president and CEO of Noctrix Health, in a release. We look forward to partnering with Noctrix’s outstanding management team as they scale and address a significant unmet need.”Leadership ExpansionAlso to support its US launch, Noctrix Health has appointed two new executives: